

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/779,152	02/08/2001	Susan L. Acton	MNI-172CP2	4228
959	7590 12/12/2001			
LAHIVE & COCKFIELD			EXAMINER	
28 STATE STREET BOSTON, MA 02109			CHAKRABAR	TI, ARUN K
			ART UNIT	PAPER NUMBER
			1655	<u></u>
			DATE MAILED: 12/12/2001	1

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/779,152

Applicant(s)

Acton

Examiner

Arun Chakrabarti

Art Unit **1655**



	· · · · · · · · · · · · · · · · · · ·			
	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address		
A SH	for Reply ORTENED STATUTORY PERIOD FOR REPLY IS SET	TO EXPIRE1 MONTH(S) FROM		
- Exter aft - If the be	ter SIX (6) MONTHS from the mailing date of this communic period for reply specified above is less than thirty (30) days peconsidered timely.	a, a reply within the statutory minimum of thirty (30) days will		
co - Failui - Any i	ommunication. re to reply within the set or extended period for reply will, by	period will apply and will expire SIX (6) MONTHS from the mailing date of this y statute, cause the application to become ABANDONED (35 U.S.C. § 133). It mailing date of this communication, even if timely filed, may reduce any		
Status	,			
1) 🔀	Responsive to communication(s) filed on 2/8/01, 3	/2/01, 3/24/01 and 10/1/01		
2a) 🗌	This action is FINAL . 2b) 🔀 This ac	tion is non-final.		
<i>3)</i> 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.			
Disposi	tion of Claims			
4) X	Claim(s) <u>1-38</u>	is/are pending in the application.		
- 4	4a) Of the above, claim(s)	is/are withdrawn from consideration.		
5)	Claim(s)	is/are allowed.		
<i>6)</i> 🗌	Claim(s)	is/are rejected.		
	Claim(s)			
81 🗶	Claims 1-38	are subject to restriction and/or election requirement.		
Applica	ition Papers			
9) 🗆	The specification is objected to by the Examiner.			
10)	The drawing(s) filed onis/are	e objected to by the Examiner.		
11)				
12)	The oath or declaration is objected to by the Exam	iner.		
Priority	under 35 U.S.C. § 119			
13)	Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d).		
a) 🗆	☐ All bl☐ Some* cl☐ None of:			
	1. \square Certified copies of the priority documents have	ve been received.		
	2. \square Certified copies of the priority documents have			
	3. Copies of the certified copies of the priority of application from the International Bure dee the attached detailed Office action for a list of the			
14)	Acknowledgement is made of a claim for domestic	•		
Attachm				
	lotice of References Cited (PTO-892)	18] Interview Summary (PTO-413) Paper No(s).		
	otice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)		
17) 🗌 In	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:		

Application/Control Number: 09/779,152

Art Unit:

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-22 and 34-38, drawn to method of determining disease and prediction of hormone therapy by nucleic acid hybridization, classified in class 435, subclass 6.
 - II. Claims 23-33, drawn to kit containing nucleic acids, classified in class 536, subclass 22.1+.
- 2. The inventions are distinct, each from the other because of the following reasons: Inventions of Groups I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the nucleic acid products of Group II can be used in the method of determining disease and prediction of hormone therapy by nucleic acid hybridization of Group II or can be used to make RNA or protein or can be used to make antisense nucleic acid for gene therapy.
- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/779,152

Art Unit:

4. A telephone call was made to DeAnn Smith on November 15, 2001 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CAR 1.143).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CAR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CAR 1.48(b) and by the fee required under 37 CAR 1.17(I).

Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph. D., whose telephone number is (703) 306-5818. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-7401.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Art Unit:

Arun Chakrabarti,

Patent Examiner

November 29, 2001